The risk of coronary artery disease after heart transplantation is increased in patients receiving low‐dose cyclosporine, regardless of blood cyclosporine levels
Open Access
- 1 September 1997
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 20 (9) , 767-772
Abstract
Background: Coronary artery disease (CAD) of allografted hearts is the main cause of late mortality after cardiac transplant, but its etiology is still undetermined.Hypothesis: This study was undertaken to evaluate the relevance of several risk factors, including cyclosporine (CsA) dose and blood CsA levels, to the incidence of CAD.Methods: In 163 heart transplants performed between November 1985 and August 1994 at our Institution, CAD was diagnosed by coronary angiography or at postmortem examination. Patients in whom postmortem examination or coronary angiography was not performed, as well as those < 15 years of age and those who died within 1 month of surgery, were excluded from the study. The following risk factors were analyzed: recipient age, gender, pretransplant diagnosis, donor age, number of human leukocyte antigen (HLA)‐AB mismatches, cytomegalovirus serology, mean serum cholesterol and triglyceride levels, the number of treated acute rejections, mean weighted CsA dose (CsA dosew) and weighted blood CsA levels (blood CsA levelw).Results:Coronary artery disease was diagnosed in 32 patients (19.6%). A low mean CsA dosew was the only significant predictor for CAD at multivariate analysis (p 4 mg/kg/day, the 8.9 year probability of their remaining CAD free was 69% [confidence interval (CI) 50–87%] in comparison with 31% (CI0–65%) in patients receiving a CsA dosew < 4 mg/kg/day.Conclusion:In our experience, a low CsA maintenance dose is the main risk factor for CAD, irrespective of blood CsA levels.Keywords
This publication has 24 references indexed in Scilit:
- Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients.1994
- CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTSTransplantation, 1994
- Long-Term Efficacy and Safety of Cyclosporine in Renal-Transplant RecipientsNew England Journal of Medicine, 1994
- LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1993
- RISK FACTOR ANALYSIS FOR THE MAJOR HAZARDS FOLLOWING HEART TRANSPLANTATION—REJECTION, INFECTION, AND CORONARY OCCLUSIVE DISEASETransplantation, 1991
- Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infectionThe American Journal of Cardiology, 1989
- Retransplantation for severe accelerated coronary artery disease in heart transplant recipientsThe American Journal of Cardiology, 1988
- Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findingsJACC, 1988
- Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone.Circulation, 1987
- Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.BMJ, 1986